RT Journal Article
T1 Prostate cancer screening: guidelines review and laboratory issues.
A1 Filella, Xavier
A1 Albaladejo, María Dolores
A1 Allué, Juan Antonio
A1 Castaño, Miguel Angel
A1 Morell-Garcia, Daniel
A1 Ruiz, Maria Àngels
A1 Santamaría, María
A1 Torrejón, María José
A1 Giménez, Nuria
K1 clinical practice guidelines
K1 prostate cancer
K1 prostate-specific antigen (PSA)
K1 screening
AB Background Prostate-specific antigen (PSA) remains as the most used biomarker in the detection of early prostate cancer (PCa). Clinical practice guidelines (CPGs) are produced to facilitate incorporation of evidence into clinical practice. This is particularly useful when PCa screening remains controversial and guidelines diverge among different medical institutions, although opportunistic screening is not recommended. Methods We performed a systematic review of guidelines about PCa screening using PSA. Guidelines published since 2008 were included in this study. The most updated version of these CPGs was used for the evaluation. Results Twenty-two guidelines were selected for review. In 59% of these guidelines, recommendations were graded according to level of evidence (n = 13), but only 18% of the guidelines provided clear algorithms (n = 4). Each CPG was assessed using a checklist of laboratory issues, including pre-analytical, analytical, and post-analytical factors. We found that laboratory medicine specialists participate in 9% of the guidelines reviewed (n = 2) and laboratory issues were frequently omitted. We remarked that information concerning the consequences of World Health Organization (WHO) standard in PSA testing was considered by only two of 22 CPGs evaluated in this study. Conclusions We concluded that the quality of PCa early detection guidelines could be improved properly considering the laboratory issues in their development.
YR 2019
FD 2019
LK http://hdl.handle.net/10668/14004
UL http://hdl.handle.net/10668/14004
LA en
DS RISalud
RD Apr 12, 2025